Clinical Utility of Thromboelastography to predict complications in Covid-19
Not Applicable
Completed
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/09/036225
- Lead Sponsor
- Prithvishree Ravindra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 168
Inclusion Criteria
Patients diagnosed with COVID-19, presenting to Emergency Department
Exclusion Criteria
Patients who have known bleeding disorders
Patients who do not consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A.To document the Thromboelastography (TEG) findings of COVID19 patients <br/ ><br>B.To explore the utility of TEG to predict coagulopathy of COVID19 patients <br/ ><br>C. To predict mortality and morbidity of patients using TEG in COVID-19 patients <br/ ><br>Timepoint: Baseline <br/ ><br>Discharge <br/ ><br>1 month
- Secondary Outcome Measures
Name Time Method A.To document the Thromboelastography (TEG) findings of COVID19 patients <br/ ><br>B.To explore the utility of TEG to predict coagulopathy of COVID19 patients <br/ ><br>C. To predict mortality and morbidity of patients using TEG in COVID-19 patients <br/ ><br>Timepoint: Baseline <br/ ><br>Discharge <br/ ><br>1 month <br/ ><br>